Diagnostic yield of EBUS-TBNA for lymphoma and review of the literature.
OBJECTIVE
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), which enables cytological examination of mediastinal lymph node (LN) aspiration samples, is a safe and minimally invasive method for diagnosis and staging of lung cancer and diagnosis of diseases affecting mediastinal LNs. In this study, we investigated the yield of EBUS-TBNA for diagnosis of lymphoma and reviewed the literature since the British Thoracic Society (BTS) guidelines were published.


METHODS
We retrospectively evaluated our database for patients who underwent EBUS between March 2011 and December 2014. One hundred eighty-nine patients with isolated mediastinal lymphadenopathy were included in the study. Patients with other causes of lymphadenopathy, such as lung cancer or extrathoracic malignancy, and those with pulmonary lesions accompanying mediastinal lymphadenopathy were excluded from the study. Patients with final diagnosed lymphoma were included in the study on the basis of a history of lymphoma or newly evaluated mediastinal lymphadenopathy. The sensitivity and negative predictive value (NPV) of EBUS-TBNA were calculated.


RESULTS
There were 13 patients with the final diagnosis of lymphoma. Eleven of them were new diagnoses and 2 patients were known chronic lymphocytic leukemia (CLL), and underwent EBUS-TBNA for determination of recurrence. Twelve EBUS-TBNA procedures were performed for suspected new cases. Three (25%) were diagnostic, 2 (16.7%) were suspicious for lymphoma and underwent further interventions for definite diagnosis, and 7 (58.3%) were false negative. All 3 patients diagnosed with EBUS-TBNA were non-Hodgkin lymphoma (NHL). None of the Hodgkin lymphoma (HL) cases could be diagnosed with EBUS-TBNA. The overall diagnostic sensitivity and NPV of EBUS-TBNA in detecting lymphoma was 65% and 96.1%, respectively. For the newly diagnosed lymphoma cases, EBUS-TBNA had a sensitivity of 61.1%.


CONCLUSIONS
In conclusion, we believe that since the publication of the BTS guidelines, the value of EBUS-TBNA in the diagnosis of lymphoma still remains controversial. EBUS-TBNA can be the first diagnostic modality in diagnosis of recurrent lymphomas. However, for suspected new cases, especially for HL, the diagnostic yield of EBUS-TBNA is low and negative results do not exclude lymphoma. Further interventions such as mediastinoscopy should be performed for high-suspicion patients.
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital, İzmir, Turkey.
Onur Fevzi
OF
Erer
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital, İzmir, Turkey.
Serhat
S
Erol
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital, İzmir, Turkey.
Ceyda
C
Anar
Department of Pathology, İzmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital, İzmir, Turkey.
Zekiye
Z
Aydoğdu
Department of Chest Diseases, İzmir Dr. Suat Seren Chest Diseases and Surgery Training Hospital, İzmir, Turkey.
Serir Aktoğu
SA
Özkan